Guyasuta Investment Advisors Inc. Reduces Position in Stryker Co. (NYSE:SYK)

Guyasuta Investment Advisors Inc. lessened its position in shares of Stryker Co. (NYSE:SYK) by 9.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,765 shares of the medical technology company’s stock after selling 181 shares during the quarter. Guyasuta Investment Advisors Inc.’s holdings in Stryker were worth $635,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in SYK. Dunhill Financial LLC grew its stake in Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after buying an additional 37 shares during the last quarter. Darwin Wealth Management LLC purchased a new position in shares of Stryker in the 3rd quarter valued at approximately $36,000. Activest Wealth Management purchased a new position in shares of Stryker in the 4th quarter valued at approximately $36,000. Crews Bank & Trust purchased a new position in shares of Stryker in the 4th quarter valued at approximately $39,000. Finally, Hara Capital LLC purchased a new position in shares of Stryker in the 3rd quarter valued at approximately $42,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.90% of the stock is owned by company insiders.

Stryker Price Performance

SYK stock opened at $385.05 on Friday. The stock has a 50-day moving average price of $377.31 and a two-hundred day moving average price of $366.30. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The company has a market cap of $146.79 billion, a PE ratio of 49.62, a price-to-earnings-growth ratio of 2.98 and a beta of 0.96.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the firm earned $3.46 earnings per share. As a group, research analysts predict that Stryker Co. will post 13.49 EPS for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Wall Street Analyst Weigh In

SYK has been the topic of several analyst reports. UBS Group lifted their target price on Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Wells Fargo & Company lifted their price objective on Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Citigroup lifted their price objective on Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Canaccord Genuity Group boosted their price target on Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Finally, Royal Bank of Canada boosted their price target on Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $420.68.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.